Dabigatran etexilate and Fall - a phase IV clinical study of FDA data

Summary:

Fall is reported as a side effect among people who take Dabigatran etexilate (dabigatran etexilate), especially for people who are female, 60+ old, have been taking the drug for 1 - 2 years also take Metformin, and have High blood pressure.

The phase IV clinical study analyzes which people have Fall when taking Dabigatran etexilate. It is created by eHealthMe based on reports of 890 people who have side effects when taking Dabigatran etexilate from the FDA, and is updated regularly.

What is Dabigatran etexilate?

Dabigatran etexilate has active ingredients of dabigatran etexilate. eHealthMe is studying from 908 Dabigatran etexilate users. Check the latest studies of Dabigatran etexilate.

What is Fall?

Fall is found to be associated with 3,235 drugs and 3,759 conditions by eHealthMe. Check the latest studies of Fall.

On Aug, 05, 2026

890 people reported to have side effects when taking Dabigatran etexilate.
Among them, 55 people (6.18%) have Fall.

Among these 55 people:

How long have people been on Dabigatran etexilate when they have Fall? *

What is the gender of people who have Fall when taking Dabigatran etexilate? *

female: 69.57 %
male: 30.43 %

What is the age of people who have Fall when taking Dabigatran etexilate? *

What are other drugs people take besides Dabigatran etexilate? *

Metformin: 21 people, 38.18%
Pantoprazole: 19 people, 34.55%
Symbicort: 13 people, 23.64%
Esbriet: 11 people, 20.00%
Isosorbide Mononitrate: 10 people, 18.18%
Zolpidem: 9 people, 16.36%
Hydrochlorothiazide: 9 people, 16.36%
Furosemide: 9 people, 16.36%
Spironolactone: 9 people, 16.36%
Acetaminophen: 9 people, 16.36%

What are other side effects people have besides Fall? *

Dizziness: 20 people, 36.36%
Nausea (feeling of having an urge to vomit): 19 people, 34.55%
Abdominal Pain Upper: 19 people, 34.55%
Dyspnea (difficult or laboured breathing): 17 people, 30.91%
Hypotension (abnormally low blood pressure): 14 people, 25.45%
Malaise (a feeling of general discomfort or uneasiness): 13 people, 23.64%
Mobility Decreased (ability to move is reduced): 13 people, 23.64%
Itching: 13 people, 23.64%
Pneumonia: 13 people, 23.64%
Insomnia (sleeplessness): 13 people, 23.64%

What are the existing conditions these people have? *

Idiopathic Pulmonary Fibrosis (chronic lung disease): 11 people, 20.00%
High Blood Pressure: 11 people, 20.00%
Type 2 Diabetes: 8 people, 14.55%
Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 8 people, 14.55%
Cardiac Failure: 8 people, 14.55%
Constipation: 8 people, 14.55%
Pain: 8 people, 14.55%
Depression: 8 people, 14.55%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 7 people, 12.73%
Cough: 7 people, 12.73%

* Approximation only. Some reports may have incomplete information.

Do you take Dabigatran etexilate and have Fall?

- Check whether Fall is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Dabigatran etexilate:

Dabigatran etexilate (908 reports)

Fall treatments and more:

Fall (403,513 reports)

Browse all side effects of Dabigatran etexilate:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Fall:

Fall (3,235 drugs)

Browse all the conditions that are associated with Fall:

Fall (3,759 conditions)

Related publications that referenced our studies

Fasullo, S., Davì, S., Cosenza, G., Di Franco, F., La Manna, N., Giubilato, A., ... & Maringhini, G. , "Acute agranulocytosis after oral administration of dabigatran: a rare case report and a short review of literature", Journal of thrombosis and thrombolysis, 2018 Jan .
Fasullo, S., Davì, S., Cosenza, G., Di Franco, F., La Manna, N., Giubilato, A., ... & Maringhini, G. , "Acute agranulocytosis after oral administration of dabigatran: a rare case report and a short review of literature", Journal of thrombosis and thrombolysis, 2018 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on dabigatran etexilate (the active ingredients of Dabigatran etexilate) and Dabigatran etexilate (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.